{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:18Z","timestamp":1775107398308,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T00:00:00Z","timestamp":1559001600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1007\/s00108-019-0625-4","type":"journal-article","created":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:24:39Z","timestamp":1559039079000},"page":"761-768","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pharmakologische Therapie der Alzheimer-Demenz","Drug treatment of Alzheimer\u2019s dementia"],"prefix":"10.1007","volume":"60","author":[{"given":"P.","family":"M\u00fcller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Fendt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. G.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,28]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"CD005593","DOI":"10.1002\/14651858.CD005593","volume":"1","author":"J Birks","year":"2006","unstructured":"Birks J (2006) Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst Rev 1:CD5593. \n                    https:\/\/doi.org\/10.1002\/14651858.CD005593","journal-title":"Cochrane Database Syst Rev"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"CD003120","DOI":"10.1002\/14651858.CD003120.pub3","volume":"1","author":"J Birks","year":"2009","unstructured":"Birks J, Grimley Evans J (2009) Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 1:CD3120. \n                    https:\/\/doi.org\/10.1002\/14651858.CD003120.pub3","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"625_CR3","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/WCO.0b013e32835a3432","volume":"25","author":"H Braak","year":"2012","unstructured":"Braak H, Del Tredici K (2012) Where, when, and in what form does sporadic Alzheimer\u2019s disease begin? Curr Opin Neurol 25(6):708\u2013714. \n                    https:\/\/doi.org\/10.1097\/WCO.0b013e32835a3432","journal-title":"Curr Opin Neurol"},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"518901","DOI":"10.1155\/2012\/518901","volume":"2012","author":"R Cacabelos","year":"2012","unstructured":"Cacabelos R, Mart\u00ednez R, Fern\u00e1ndez-Novoa L, Carril JC, Lombardi V, Carrera I, Corzo L, Tellado I, Leszek J, McKay A, Takeda M (2012) Genomics of dementia: aPOE- and CYP2D6-related Pharmacogenetics. Int J Alzheimers Dis 2012:518901. \n                    https:\/\/doi.org\/10.1155\/2012\/518901","journal-title":"Int J Alzheimers Dis"},{"issue":"7","key":"625_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","volume":"14","author":"EE Congdon","year":"2018","unstructured":"Congdon EE, Sigurdsson EM (2018) Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 14(7):399\u2013415. \n                    https:\/\/doi.org\/10.1038\/s41582-018-0013-z","journal-title":"Nat Rev Neurol"},{"key":"625_CR6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","volume":"8","author":"J Cummings","year":"2016","unstructured":"Cummings J, Aisen PS, Dubois B, Fr\u00f6lich L, Jack CR, Jones RW, Morris JC, Raskin J, Dowsett SA, Scheltens P (2016) Drug development in Alzheimer\u2019s disease: the path to 2025. Alzheimers Res Ther 8:39. \n                    https:\/\/doi.org\/10.1186\/s13195-016-0207-9","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"625_CR7","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.trci.2017.05.002","volume":"3","author":"J Cummings","year":"2017","unstructured":"Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K (2017) Alzheimer\u2019s disease drug development pipeline: 2017. Alzheimers Dement (N Y) 3(3):367\u2013384. \n                    https:\/\/doi.org\/10.1016\/j.trci.2017.05.002","journal-title":"Alzheimers Dement (N Y)"},{"key":"625_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-53875-3","volume-title":"S3-Leitlinie Demenzen. Interdisziplin\u00e4re S3-Praxisleitlinien","author":"DGPPN","year":"2017","unstructured":"DGPPN, DGN (2017) S3-Leitlinie Demenzen. Interdisziplin\u00e4re S3-Praxisleitlinien. Springer, Berlin, Heidelberg"},{"key":"625_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-662-53875-3","volume-title":"S3-Leitlinie Demenzen. Interdisziplin\u00e4re S3-Praxisleitlinien","author":"DGPPN","year":"2017","unstructured":"DGPPN, Deutsche Gesellschaft f. Neurologie, Springer-Verlag GmbH (2017) S3-Leitlinie Demenzen. Interdisziplin\u00e4re S3-Praxisleitlinien. Springer, Berlin, Heidelberg"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1515\/9783110411003-003","volume-title":"Handbuch Alzheimer-Krankheit","author":"G Doblhammer","year":"2018","unstructured":"Doblhammer G, Fink A, Fritze T, Nerius M (2018) 2. Demographische Entwicklung und Epidemiologie von Demenzerkrankungen. In: Jessen F (Hrsg) Handbuch Alzheimer-Krankheit. De Gruyter, Berlin, Boston, S 13\u201334"},{"issue":"1","key":"625_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2174\/156720508783884585","volume":"5","author":"M Fern\u00e1ndez-Mart\u00ednez","year":"2008","unstructured":"Fern\u00e1ndez-Mart\u00ednez M, Castro J, Molano A, Zarranz JJ, Rodrigo RM, Ortega R (2008) Prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease and vascular dementia. Curr Alzheimer Res 5(1):61\u201369","journal-title":"Curr Alzheimer Res"},{"key":"625_CR12","volume-title":"Demenzen in Theorie und","year":"2011","unstructured":"F\u00f6rstl H (Hrsg) (2011) Demenzen in Theorie und, 3.\u00a0Aufl. Springer, Berlin, Heidelberg","edition":"3"},{"issue":"11","key":"625_CR13","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s15202-014-0812-z","volume":"15","author":"H Gutzmann","year":"2014","unstructured":"Gutzmann H (2014) Aktuelle Therapieoptionen bei Demenz. DNP 15(11):54\u201363. \n                    https:\/\/doi.org\/10.1007\/s15202-014-0812-z","journal-title":"DNP"},{"issue":"3","key":"625_CR14","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1055\/a-0658-6720","volume":"144","author":"L Hausner","year":"2019","unstructured":"Hausner L, Fr\u00f6lich L (2019) Medikament\u00f6se Therapie der Alzheimer-Demenz mit Antidementiva. Dtsch Med Wochenschr 144(3):156\u2013160. \n                    https:\/\/doi.org\/10.1055\/a-0658-6720","journal-title":"Dtsch Med Wochenschr"},{"issue":"2","key":"625_CR15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s00108-016-0182-z","volume":"58","author":"W Hofmann","year":"2017","unstructured":"Hofmann W (2017) Demenz und internistische Komorbidit\u00e4t. Internist (Berl) 58(2):105\u2013116. \n                    https:\/\/doi.org\/10.1007\/s00108-016-0182-z","journal-title":"Internist (Berl)"},{"key":"625_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2018.01.040","author":"C H\u00f6lscher","year":"2018","unstructured":"H\u00f6lscher C (2018) Novel dual GLP-1\/GIP receptor agonists show neuroprotective effects in Alzheimer\u2019s and Parkinson\u2019s disease models. Neuropharmacology. \n                    https:\/\/doi.org\/10.1016\/j.neuropharm.2018.01.040","journal-title":"Neuropharmacology"},{"issue":"31\u201332","key":"625_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3238\/arztebl.2010.0543","volume":"107","author":"S Holt","year":"2010","unstructured":"Holt S, Schmiedl S, Th\u00fcrmann PA (2010) Potentially inappropriate medications in the elderly: the PRISCUS list. Dtsch Arztebl Int 107(31\u201332):543\u2013551. \n                    https:\/\/doi.org\/10.3238\/arztebl.2010.0543","journal-title":"Dtsch Arztebl Int"},{"issue":"4","key":"625_CR18","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1056\/NEJMoa1705971","volume":"378","author":"LS Honig","year":"2018","unstructured":"Honig LS, Vellas B, Woodward M, Boada M, Bullock R, Borrie M, Hager K, Andreasen N, Scarpini E, Liu-Seifert H, Case M, Dean RA, Hake A, Sundell K, Poole Hoffmann V, Carlson C, Khanna R, Mintun M, DeMattos R, Selzler KJ, Siemers E (2018) Trial of Solanezumab for mild dementia Due to Alzheimer\u2019s disease. N\u00a0Engl J Med 378(4):321\u2013330. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1705971","journal-title":"N Engl J Med"},{"issue":"10","key":"625_CR19","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1106668","volume":"366","author":"R Howard","year":"2012","unstructured":"Howard R, McShane R, Lindesay J et al (2012) Donepezil and memantine for moderate-to-severe Alzheimer\u2019s disease. N\u00a0Engl J Med 366(10):893\u2013903. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1106668","journal-title":"N Engl J Med"},{"issue":"4","key":"625_CR20","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack","year":"2018","unstructured":"Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA Research Framework: toward a\u00a0biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. \n                    https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"issue":"1","key":"625_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s40478-019-0664-z","volume":"7","author":"S Jadhav","year":"2019","unstructured":"Jadhav S, Avila J, Sch\u00f6ll M, Kovacs GG, K\u00f6vari E, Skrabana R, Evans LD, Kontsekova E, Malawska B, de Silva R, Buee L, Zilka N (2019) A walk through tau therapeutic strategies. Acta Neuropathol Commun 7(1):22. \n                    https:\/\/doi.org\/10.1186\/s40478-019-0664-z","journal-title":"Acta Neuropathol Commun"},{"issue":"2","key":"625_CR22","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00108-016-0180-1","volume":"58","author":"JW Kraft","year":"2017","unstructured":"Kraft JW (2017) Medikament\u00f6se Therapie demenzieller Erkrankungen. Internist (Berl) 58(2):117\u2013124. \n                    https:\/\/doi.org\/10.1007\/s00108-016-0180-1","journal-title":"Internist (Berl)"},{"issue":"4","key":"625_CR23","doi-asserted-by":"publisher","first-page":"e010767","DOI":"10.1136\/bmjopen-2015-010767","volume":"6","author":"K Laver","year":"2016","unstructured":"Laver K, Dyer S, Whitehead C, Clemson L, Crotty M (2016) Interventions to delay functional decline in people with dementia: a\u00a0systematic review of systematic reviews. BMJ Open 6(4):e10767. \n                    https:\/\/doi.org\/10.1136\/bmjopen-2015-010767","journal-title":"BMJ Open"},{"issue":"11 Suppl 5","key":"625_CR24","first-page":"4","volume":"54","author":"A Lobo","year":"2000","unstructured":"Lobo A, Launer LJ, Fratiglioni L, Andersen K, Di Carlo A, Breteler MM, Copeland JR, Dartigues JF, Jagger C, Martinez-Lage J, Soininen H, Hofman A (2000) Prevalence of dementia and major subtypes in europe: a collaborative study of population-based cohorts. Neurologic diseases in the elderly research group. Baillieres Clin Neurol 54(11 Suppl 5):4\u20139","journal-title":"Baillieres Clin Neurol"},{"issue":"7","key":"625_CR25","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/S1474-4422(10)70119-8","volume":"9","author":"F Mangialasche","year":"2010","unstructured":"Mangialasche F, Solomon A, Winblad B, Mecocci P, Kivipelto M (2010) Alzheimer\u2019s disease: clinical trials and drug development. Lancet Neurol 9(7):702\u2013716. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(10)70119-8","journal-title":"Lancet Neurol"},{"key":"625_CR26","doi-asserted-by":"publisher","first-page":"15056","DOI":"10.1038\/nrdp.2015.56","volume":"1","author":"CL Masters","year":"2015","unstructured":"Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL (2015) Alzheimer\u2019s disease. Nat Rev Dis Primers 1:15056. \n                    https:\/\/doi.org\/10.1038\/nrdp.2015.56","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 2","key":"625_CR27","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00391-017-1202-x","volume":"50","author":"P M\u00fcller","year":"2017","unstructured":"M\u00fcller P, Schmicker M, M\u00fcller NG (2017) Pr\u00e4ventionsstrategien gegen Demenz. Z\u00a0Gerontol Geriatr 50(Suppl 2):89\u201395. \n                    https:\/\/doi.org\/10.1007\/s00391-017-1202-x","journal-title":"Z Gerontol Geriatr"},{"key":"625_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2019.00672","volume":"11","author":"P M\u00fcller","year":"2019","unstructured":"M\u00fcller P, Taubert M, M\u00fcller NG (2019) Physical exercise as personalized medicine for dementia prevention? Front Physiol 11:1\u20135. \n                    https:\/\/doi.org\/10.3389\/fphys.2019.00672","journal-title":"Front Physiol"},{"key":"625_CR29","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201708763","author":"A Nabers","year":"2018","unstructured":"Nabers A, Perna L, Lange J, Mons U, Schartner J, G\u00fcldenhaupt J, Saum K\u2011U, Janelidze S, Holleczek B, Rujescu D, Hansson O, Gerwert K, Brenner H (2018) Amyloid blood biomarker detects Alzheimer\u2019s disease. Embo Mol Med. \n                    https:\/\/doi.org\/10.15252\/emmm.201708763","journal-title":"Embo Mol Med"},{"key":"625_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.dadm.2019.01.008","volume":"11","author":"A Nabers","year":"2019","unstructured":"Nabers A, Hafermann H, Wiltfang J, Gerwert K (2019) A\u03b2 and tau structure-based biomarkers for a\u00a0blood- and CSF-based two-step recruitment strategy to identify patients with dementia due to Alzheimer\u2019s disease. Alzheimers Dement (amst) 11:257\u2013263. \n                    https:\/\/doi.org\/10.1016\/j.dadm.2019.01.008","journal-title":"Alzheimers Dement (amst)"},{"issue":"7691","key":"625_CR31","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, Fowler C, Li Q\u2011X, Martins R, Rowe C, Tomita T, Matsuzaki K, Ishii K, Ishii K, Arahata Y, Iwamoto S, Ito K, Tanaka K, Masters CL, Yanagisawa K (2018) High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature 554(7691):249\u2013254. \n                    https:\/\/doi.org\/10.1038\/nature25456","journal-title":"Nature"},{"issue":"4","key":"625_CR32","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nm840","volume":"9","author":"JAR Nicoll","year":"2003","unstructured":"Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003) Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a\u00a0case report. Nat Med 9(4):448\u2013452. \n                    https:\/\/doi.org\/10.1038\/nm840","journal-title":"Nat Med"},{"issue":"8","key":"625_CR33","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S1474-4422(14)70136-X","volume":"13","author":"S Norton","year":"2014","unstructured":"Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C (2014) Potential for primary prevention of Alzheimer\u2019s disease: an analysis of population-based data. Lancet Neurol 13(8):788\u2013794. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(14)70136-X","journal-title":"Lancet Neurol"},{"key":"625_CR34","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1515\/9783110411003-009","volume-title":"Handbuch Alzheimer-Krankheit","author":"O Peters","year":"2018","unstructured":"Peters O, Grimmer T, H\u00e4ussermann P, Sieber CC (2018) 8. Medikament\u00f6se Therapie. In: Jessen F (Hrsg) Handbuch Alzheimer-Krankheit. De Gruyter, Berlin, Boston, S 427\u2013484"},{"issue":"1","key":"625_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2174\/156720508783884576","volume":"5","author":"AP Porsteinsson","year":"2008","unstructured":"Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT (2008) Memantine treatment in patients with mild to moderate Alzheimer\u2019s disease already receiving a\u00a0cholinesterase inhibitor: a\u00a0randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res 5(1):83\u201389","journal-title":"Curr Alzheimer Res"},{"issue":"3","key":"625_CR36","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1111\/joim.12191","volume":"275","author":"LS Schneider","year":"2014","unstructured":"Schneider LS, Mangialasche F, Andreasen N, Feldman H, Giacobini E, Jones R, Mantua V, Mecocci P, Pani L, Winblad B, Kivipelto M (2014) Clinical trials and late-stage drug development for Alzheimer\u2019s disease: an appraisal from 1984 to 2014. J\u00a0Intern Med 275(3):251\u2013283. \n                    https:\/\/doi.org\/10.1111\/joim.12191","journal-title":"J Intern Med"},{"key":"625_CR37","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.brainres.2017.10.012","volume":"1678","author":"J Tai","year":"2018","unstructured":"Tai J, Liu W, Li Y, Li L, H\u00f6lscher C (2018) Neuroprotective effects of a\u00a0triple GLP-1\/GIP\/glucagon receptor agonist in the APP\/PS1 transgenic mouse model of Alzheimer\u2019s disease. Brain Res 1678:64\u201374. \n                    https:\/\/doi.org\/10.1016\/j.brainres.2017.10.012","journal-title":"Brain Res"},{"issue":"18","key":"625_CR38","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1055\/s-0041-103205","volume":"140","author":"M Wehling","year":"2015","unstructured":"Wehling M, Throm C (2015) Polypharmazie im Alter \u2013 klug entscheiden mit dem FORTA-Prinzip. Dtsch Med Wochenschr 140(18):1378\u20131382. \n                    https:\/\/doi.org\/10.1055\/s-0041-103205","journal-title":"Dtsch Med Wochenschr"},{"issue":"4","key":"625_CR39","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3233\/JAD-2008-15404","volume":"15","author":"DM Wilcock","year":"2008","unstructured":"Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer\u2019s disease: relevance of transgenic mouse studies to clinical trials. J\u00a0Alzheimers Dis 15(4):555\u2013569","journal-title":"J Alzheimers Dis"},{"issue":"5","key":"625_CR40","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1474-4422(16)00062-4","volume":"15","author":"B Winblad","year":"2016","unstructured":"Winblad B, Amouyel P, Andrieu S et\u00a0al (2016) Defeating Alzheimer\u2019s disease and other dementias: a\u00a0priority for European science and society. Lancet Neurol 15(5):455\u2013532. \n                    https:\/\/doi.org\/10.1016\/S1474-4422(16)00062-4","journal-title":"Lancet Neurol"},{"key":"625_CR41","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jad.2015.09.069","volume":"190","author":"Q-F Zhao","year":"2016","unstructured":"Zhao Q\u2011F, Tan L, Wang H\u2011F, Jiang T, Tan M\u2011S, Tan L, Xu W, Li J\u2011Q, Wang J, Lai T\u2011J, Yu J\u2011T (2016) The prevalence of neuropsychiatric symptoms in Alzheimer\u2019s disease: Systematic review and meta-analysis. J\u00a0Affect Disord 190:264\u2013271. \n                    https:\/\/doi.org\/10.1016\/j.jad.2015.09.069","journal-title":"J Affect Disord"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0625-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,26]],"date-time":"2020-05-26T23:34:17Z","timestamp":1590536057000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0625-4"}},"subtitle":["Aktueller Stand und Perspektiven","Status quo and perspectives"],"short-title":[],"issued":{"date-parts":[[2019,5,28]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0625-4","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,28]]},"assertion":[{"value":"28 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"P.\u00a0M\u00fcller, M.\u00a0Fendt und N.G.\u00a0M\u00fcller geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}